MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
== Physiological roles == Myo-Inositol plays an important role as the structural basis for a number of secondary messengers in eukaryotic cells, the various inositol phosphates. Glycosylated inositol phosphates (or inositol phosphate glycans, IPGs) are produced by cells exposed to insulin and mediate a range of its blood glucose-regulating outcomes. Inositol also serves as an important component of the structural lipids phosphatidylinositol (PI) and its various phosphates, the phosphatidylinositol phosphate (PIP) lipids. Glycophosphatidylinositol (or GPI), a glycosylated derivative of phosphatidylinositol formed with the sugar nucleotide UDP-GalNAc and the fatty acids palmitate or myristate, provides the anchor to which many peripheral membrane proteins are attached to cell membranes, defining the category GPI-anchored proteins.
While such infrastructure has always been associated with some risk, the dependency of Denmark and its allies on them are only increasing and is therefore posing a major threat in times of tension short of actual conflict.
=== 1: Channels/pores === α-helical protein channels such as voltage-gated ion channel (VIC), ligand-gated ion channels(LGICs) β-barrel porins such as aquaporin channel-forming toxins, including colicins, diphtheria toxin, and others Nonribosomally synthesized channels such as gramicidin Holins; which function in export of enzymes that digest bacterial cell walls in an early step of cell lysis. Facilitated diffusion occurs in and out of the cell membrane via channels/pores and carriers/porters. Note:
===== Chain of two decays ===== Now consider the case of a chain of two decays: one nuclide A decaying into another B by one process, then B decaying into another C by a second process, i.e. A → B → C. The previous equation cannot be applied to the decay chain, but can be generalized as follows. Since A decays into B, then B decays into C, the activity of A adds to the total number of B nuclides in the present sample, before those B nuclides decay and reduce the number of nuclides leading to the later sample. In other words, the number of second generation nuclei B increases as a result of the first generation nuclei decay of A, and decreases as a result of its own decay into the third generation nuclei C. The sum of these two terms gives the law for a decay chain for two nuclides:
(CH2CH2)O + HCN → HOCH2CH2CN →−H2O CH2=CH−CN Addition of hydrocyanic acid to ethylene oxide is carried out in the presence of a catalyst (sodium hydroxide and diethylamine), and dehydration of cyanohydrin occurs in the gas phase upon the catalytic action of aluminium oxide.
Sources: en.wikipedia.org
Efraim Halevy (Hebrew: אפרים הלוי; born in London, 2 December 1934); Israeli intelligence expert and diplomat; was director of Mossad and 3rd head of Israeli National Security Council; author of Man in the Shadows, covering Middle Eastern history since the late 1980s; nephew of Sir Isaiah Berlin; has written for The Washington Post, Jerusalem Post, Times of Israel, Haaretz, Foreign Affairs, Ynet News, The Forward Simon Hattenstone (born 29 December 1962 in Salford, England) journalist and writer; features writer and interviewer for The Guardian. He has also written or ghost-written a number of biographical books. Paula Heimann; (2 February 1899 – 22 October 1982), author, academic, psychiatrist and psychoanalyst who established phenomenon of countertransference as important tool of psychoanalytic treatment, publishing influential studies, texts, academic papers and monographs; member of British Psychoanalytical Society; author of monograph A contribution to the problem of sublimation and paper On counter-transference, presented at the Psychoanalytical Congress in 1949 in Zurich, led to rift with Kleinian group of analysts; later turned to the Independents group and was Margarete Mitscherlich's analyst; Alexander Mitscherlich also underwent training analysis with her. Margot Heinemann (18 November 1913 – 10 June 1992) was a British Marxist writer, drama scholar, and leading member of the Communist Party of Great Britain (CPGB).
While the galectin family as a whole has been widely recognized to be on the cell surface, the study of galectin's role in healing skin wounds is still being developed for therapeutic courses of action. Galectin-7 specifically promotes the re-epithelialization of the skin, kidney, corneal, and uterine wounds. While this protein is known for its role in epithelial homeostasis and apoptosis, it also functions as a modulator of adaptive immune responses within stratified epithelial tissues like the skin, cornea, and mucous areas. It has immunological effects that are derived from extracullar and intracellular roles like glycan binding. The response to damage and stress can modulate the secretion of epithelial-derived cytokines and promotion of immune activation or decreasing it. The enhancement of early inflammatory responses, regulation of cytokine secretion, modulation of immune-cell adhesion, apoptosis control, and altered immune landscapes in tumors are all local modulations of functions in epithelial stress responses to modulate immunity.
== Quality == The speed of freezing has a direct impact on the size and the number of ice crystals formed within a food product's cells and extracellular space. Slow freezing leads to fewer but larger ice crystals while fast freezing leads to smaller but more numerous ice crystals. This difference in ice crystal size can affect the degree of residual enzymatic activity during frozen storage via the process of freeze concentration, which occurs when enzymes and solutes present in a fluid medium are concentrated between ice crystal formations. Increased levels of freeze concentration, mediated by the formation of large ice crystals, can promote enzymatic browning. Large ice crystals can also puncture the walls of the cells of the food product which will cause a degradation of the texture of the product as well as the loss of its natural juices during thawing. That is why there will be a qualitative difference observed between food products frozen by ventilated mechanical freezing, non-ventilated mechanical freezing or cryogenic freezing with liquid nitrogen.
In 2001, Freeman reprised his role of Alex Cross in Along Came a Spider, a sequel to 1997's Kiss the Girls. The film received mixed-to-negative reviews. Susan Wloszczyna of USA Today observed that "Freeman strides with noble authority" but thought the overall film was unmemorable. In 2002, Freeman was cast opposite Ben Affleck in the spy thriller The Sum of All Fears. It is based on Tom Clancy's 1991 novel of the same name, about a plot by an Austrian Neo-Nazi to trigger a nuclear war between the United States and Russia, so that he can establish a fascist superstate in Europe. The Sum of All Fears received moderate reviews, but was a commercial success, grossing $193.9 million worldwide. Next, Freeman starred alongside Ashley Judd and Jim Caviezel in High Crimes (2002), a legal thriller based on Joseph Finder's 1998 novel of the same name. The story follows lawyer Claire (Judd), whose husband (Caviezel) is arrested and placed on trial for the murder of villagers while he was in the Marines. Although several critics were unimpressed with the story, they credited Freeman and Judd for their chemistry and performances. In 2003, Freeman appeared as God in the hit comedy Bruce Almighty with Jim Carrey and Jennifer Aniston. Next, he starred in the science fiction horror Dreamcatcher, adapted from Stephen King's 2001 novel of the same name. The film was a box-office flop, and garnered mostly negative reviews; Dreamcatcher has an approval rating of 28% on review aggregate site Rotten Tomatoes.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.